FLT3 and acute myeloid leukemia: More recent efforts have characterized proteomics in patient samples using reverse phase proteomic assays (RPPA) in a pediatric AML cohort [19] as well as focusing explicity on phosphoproteomics measurements in AML related to FLT3 activity [20], showing how measuring protein and phosphorylation activity can better stratify patients and predict drug response.